Sandalan, Proceso D.

HRN: 03-57-23  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/31/2023
CEFTAZIDIME 1GM (VIAL)
08/31/2023
09/07/2023
IV
1g
Q8
CAP-MR
Waiting Final Action 
08/31/2023
AZITHROMYCIN 500MG TABLET (TAB)
08/31/2023
09/05/2023
PO
1 Tab
OD
CAP-MR
Waiting Final Action 
08/31/2023
CEFUROXIME 1.5GM (VIAL)
08/31/2023
09/07/2023
IV
1.5g
Q8hr
Complicated UTI
08/31/2023
CEFTRIAXONE 1G (VIAL)
09/01/2023
09/07/2023
IV
1gm
Q12H
Complicated UTI
Waiting Final Action 
09/11/2023
CEFTAZIDIME 1GM (VIAL)
09/11/2023
09/17/2023
IV
1g
Q8H
CAP-MR
Waiting Final Action 
09/29/2023
CEFUROXIME 500MG (TAB)
09/29/2023
10/06/2023
PO
500mg
Q12hr
Prophylaxis
Waiting Final Action 
09/30/2023
CEFUROXIME 500MG (TAB)
09/30/2023
10/07/2023
ORAL
500mg/tab
BID
S/P Incision Biopsy Site
Waiting Final Action 
09/30/2023
MUPIROCIN 2%, 15G (TUBE)
09/30/2023
10/07/2023
TOPICAL
2%
BID
S/P Incision Biopsy Site
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: